Biopol Chemicals (BIOPOL)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 38.18% suggests strong capital efficiency if the past earnings are sustainable.
• Promoter holding of 65.81% aligns promoter interests with minority shareholders.
• Small market cap of ₹103 Cr leaves room for growth if the business genuinely recovers.
• P/E of 23.81 is not excessive if normalized earnings return, but current zero quarter undermines it.

Concerns

• Latest quarter sales and net profit are ₹0 Cr, meaning current operations are generating nothing.
• Piotroski F-Score of 3/9 indicates weak financial health and possible red flags.
• Key data like book value, ROE, and debt/equity are missing, making a Graham-style margin-of-safety analysis impossible.
• Zero dividend yield and zero reported growth offer no income or momentum support.

AI Analysis

Let me start with what I can verify. Biopol Chemicals is a ₹103 Cr market cap specialty chemical company, but the crucial numbers are either missing or alarming. The latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr. A business that currently earns nothing cannot be valued with a P/E of 23.81—that multiple is meaningless unless the next quarter brings real earnings. Graham taught me to treat numbers with suspicion when they are incomplete. Here book value, ROE, and debt/equity are absent, so I cannot measure a margin of safety. The Piotroski F-Score of 3/9 reinforces my caution; it says the financial position has deteriorated. The one bright spot is ROCE of 38.18%, which would be remarkable if it came from sustainable operations. But with zero current sales, I wonder whether that return is historical, one-time, or based on a very small equity base. Promoter holding of 65.81% is encouraging—owners have skin in the game—but high ownership is not the same as a durable moat. This is not a fast grower or a stalwart; it is a business in need of proof. Until I see a quarter with real sales and profits, a clear debt profile, and honest book value, I cannot pay ₹109.95. In Graham's language, this is speculation, not investment. I would put it on the watchlist, not in the portfolio. If Biopol can show that the zero quarter was unusual and that cash generation has returned, my view might change. But in investing, you do not fix a broken story with hope; you need figures. Here the figures fail the test.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer